AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform ... apply them and then scale them at pace into the ...

By implementing strategies such as fine-tuning smaller models and real-time AI cost monitoring, financial institutions can ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

Measuring an antenna’s radiation properties is important, especially when it comes to complying with regulations and system ...

Power Metallic Inc. (the "Company" or "Power Metallic")  is pleased to provide an update on the current exploration activity ...

The “slow but consistent increase” in global temperatures is enabling climate-sensitive disease vectors, such as mosquitoes ...

Japan Tobacco delivers steady income with a 5% yield. Read why JAPAY stock could provide consistent returns and potential for ...

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal ...

PARIS - Europe may have to wait for its own capability to suppress long-range enemy air defenses until at least 2033, with ...

The study conducted by IIT Roorkee is supported by the Indian Council of Medical Research (ICMR). It has been published in a ...

Research on the insectome in and around broiler breeder pullet farms has identified new potential vectors of Histomonas meleagridis, the protozoa that ...

You don’t want to compete with someone who has an AI at their shoulder,” says Steve Blank. He has co-founded four startups, ...